Pyxis Oncology, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Pyxis Oncology, Inc. | PYXS - NASDAQ |
$14.00-$16.00 | $16.00 | $19.00 | 10.5 million | 10/8/2021 |
| BofA Securities, Jefferies, Credit Suisse, William Blair | ||||||
Co-Manager(s): LifeSci Capital | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-09-17 Terms Added 2021-10-04 Terms Changed 2021-10-07 | ||||||
Pyxis Oncology, Inc. Quote & Chart - Click for current quote - PYXS
IPO Boutique aggregates information on public companies and private companies, such as "PYXS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Pyxis Oncology, Inc. (adapted from Pyxis Oncology, Inc. prospectus):
They are a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PYXS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.